Consistent with the preclinical studies, findings from a Phase 2A study in subjects with DMD (N = 48) indicated that in humans vamorolone at 6 mg/kg/day reduced serum osteocalcin levels after 14 days of dosing by ~33% [27]. This evidence concerns the gene BGLAP and Duchenne muscular dystrophy.